Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Celcuity Inc. Common Stock

CELC

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Last trade $57.56
Day change -$3.01 (-4.97%)
Day range $56.83 – $60.74
Volume 960,968
Market cap $2.96B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.96B
Price / earnings
—
Price / book
-40.03×
Price / sales
—
EV / sales
—
EV / EBITDA
-14.57×

Profitability

Earnings per share
-$5.23
Return on assets
-35.22%
Return on equity
345.78%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-10.18×
Current ratio
14.62×
Quick ratio
14.59×
Cash ratio
3.86×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$213.48M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CELC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$39.8M$35.04M$17.44M$11.57M$12.42M$7.59M$6.37M$2.96M
Research and development$37.52M$31.08M$33.06M$37.63M$30.43M$36.42M$29.76M$33.47M
Total operating expenses$77.32M$66.12M$50.51M$49.2M$42.85M$44.01M$36.13M$36.43M
Operating income-$77.32M-$66.12M-$50.51M-$49.2M-$42.85M-$44.01M-$36.13M-$36.43M
Interest expense-$2.69M-$5.42M-$6.09M-$6.17M-$4.6M-$3.2M-$3.18M-$3.28M
Income before taxes-$73.34M-$78.86M-$52.84M-$50.97M-$43.8M-$45.27M-$37M-$36.65M
Income taxes$0$0$0$0$0$0$0$0
Net income-$73.34M-$78.86M-$52.84M-$50.97M-$43.8M-$45.27M-$37M-$36.65M
Net income attributable to common shareholders-$73.34M-$78.86M-$52.84M-$50.97M-$43.8M-$45.27M-$37M-$36.65M
EBITDA-$77.26M-$66.06M-$50.46M-$49.15M-$42.81M-$43.97M-$36.1M-$36.4M
Basic earnings per share-$1.33-$1.44-$0.97-$0.97-$0.92-$1.04-$0.86-$0.85
Diluted earnings per share-$1.33-$1.44-$0.97-$0.97-$0.92-$1.04-$0.86-$0.85

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Celcuity announced updated subgroup analyses from the Phase 3 VIKTORIA-1 study showing that gedatolisib triplet and doublet regimens significantly improved median progression-free survival compared to alpelisib plus fulvestrant in HR+/HER2- advanced breast cancer patients with PIK3CA mutations. The gedatolisib triplet achieved 21.5 months median PFS in patients without liver metastases versus 9.1 months for alpelisib, with lower discontinuation rates due to adverse events (5% vs 19%).

Zacks Investment Research

New Strong Sell Stocks for October 14th

Zacks has added three stocks to its Strong Sell list: adidas AG with a 5.1% downward earnings revision, Celcuity Inc. with a 15.3% downward revision, and Collective Mining Ltd. with a 31.8% downward earnings revision over the last 60 days.

The Motley Fool

Why Celcuity Stock Was a Winner on Wednesday

Celcuity stock gained 2.8% on Wednesday as the biotech company launched its first FDA-approved drug, Revtorpyk, for HR+/HER2 breast cancer treatment. The company also introduced support services for patients and physicians. The stock outperformed the broader market, which saw the S&P 500 decline 0.3%.

GlobeNewswire Inc.

NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

Law firm Kessler Topaz Meltzer & Check is investigating Celcuity Inc. for potential securities law violations following the company's announcement of a delayed drug launch for its FDA-approved breast cancer therapy Revtorpyk. The delayed launch timeline, announced on July 14, 2026, fell short of analyst expectations and triggered a 17% stock price decline. The firm is encouraging investors who suffered losses to contact them regarding potential legal rights.

GlobeNewswire Inc.

CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Celcuity Inc. for potential securities violations following the company's announcement of FDA approval for breast cancer therapy Revtorpyk with a delayed commercial launch in late Q3 2026. The delayed timeline, contrary to analyst expectations, triggered a 17.6% stock price decline on July 15, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.